Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP+HA-23 in Knee Osteoarthritis
NCT06685120Recruiting
- Sponsor
- Istituto Ortopedico Rizzoli
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Polymer-based Nanoparticles, Adipose-derived MSCs, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of platelet-rich plasma and hyaluronic acid in knee osteoarthritis (OA) (3 arms), sponsored by Istituto Ortopedico Rizzoli. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
platelet-rich plasmahyaluronic acid
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06685120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685120.